YTHDF2 and lymphoma: Our recent data identified that YTHDF2-m6A-CD19 mediated malignant B cell immune escape from CD19 CAR-T cell therapy, suggesting that YTHDF2 serves as a promising therapeutic target for malignant B cells including B cell leukemia or lymphomas (Fig. 4L).